secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001213900-26-002187
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics Phase 1 CER-1236 trial shows safety, 61-day transfusion-free interval; expands to MDS/MF
--------------------------------------------------------------------------------

- First cohort completed DLT period with no CRS, ICANS, or treatment-related AEs reported.
- Second patient (MDS/AML) had 61-day platelet transfusion-free interval after CER-1236 treatment.
- FDA amendment filed to include advanced MDS and myelofibrosis as additional cohorts.
- Company to host analyst call on Jan 7, 2026 at 5:00 PM ET to discuss progress and strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026002187/0001213900-26-002187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026002187/ea0272086-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-002187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer